Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
150 hedge funds and large institutions have $1.59B invested in Acceleron Pharma in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 43 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
16% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 43
9% more funds holding
Funds holding: 137 → 150 (+13)
4% less capital invested
Capital invested by funds: $1.66B → $1.59B (-$69M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
67% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.8M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$14.1M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13.3M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.3M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$29.8M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$20.7M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$8.49M |
| 4 |
First Manhattan
New York
|
-$6.99M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$5.81M |
XLRN Hedge Fund Activity: Q1 2018 in Review
150 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2018, worth a combined $1.59B — down 4.2% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new XLRN positions and 14 closed out — a net gain of 15 holders — while 50 added to existing stakes and 43 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $18.8M. The largest seller was BlackRock, cutting an estimated $29.8M.
- 150 institutional investors held Acceleron Pharma (XLRN) as of Q1 2018, up from 137 in Q4 2017.
- Funds reported $1.59B of Acceleron Pharma stock for Q1 2018, down 4.2% quarter-over-quarter.
- 29 funds opened new Acceleron Pharma positions in Q1 2018 and 14 closed out, a net change of +15 holders.
- The largest Acceleron Pharma buyer in Q1 2018 was T. Rowe Price Associates, an estimated $18.8M added.
- The largest Acceleron Pharma seller in Q1 2018 was BlackRock, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2018.